Condition (MeSH)
Sickle Cell Trait
ClinicalTrials.gov lists 43 trials for Sickle Cell Trait or a narrower condition beneath it. National Heart, Lung, and Blood Institute (NHLBI) has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
43 of the 43 trials are tagged with Sickle Cell Trait itself; the rest are tagged with a narrower condition beneath it.
When did Sickle Cell Trait trials start? (18)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 8
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 2 |
| 2024 | 4 |
| 2023 | 3 |
| 2022 | 5 |
| 2021 | 8 |
| 2020 | 2 |
| 2019 | 2 |
| 2018 | 1 |
| 2017 | 3 |
Showing 10 of 18 earlier years.
No forecast is made for this condition: it averages 3.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Sickle Cell Trait trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 6 |
| Phase 1/2 | 1 |
| Phase 2 | 1 |
| Phase 3 | 6 |
| Not applicable | 9 |
| Observational | 20 |
How many Sickle Cell Trait trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 7 |
| Active, not recruiting | 4 |
| Completed | 21 |
| Terminated | 3 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Sickle Cell Trait trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | 4 |
| Pfizer | 3 |
| Forma Therapeutics, Inc. | 2 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2 |
| Novartis Pharmaceuticals | 2 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Sickle Cell Trait? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Inclacumab | 2 |
| Crizanlizumab | 2 |
| Etavopivat | 2 |
| Sirolimus | 2 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Total Body Irradiation | 2 |
| Rituximab or Biosimilar | 1 |
| 131I-apamistmab | 1 |
| Ticagrelor (Brilique) 90 | 1 |
| Etavopivat Tablets Low dose | 1 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Sickle Cell Trait trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pneumonia | 23 | 3 |
| Anaemia | 16 | 2 |
| COVID-19 | 16 | 2 |
| Malaria | 14 | 2 |
| Pulmonary embolism | 8 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Sickle Cell Trait? (55)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Erythrocyte type 1 equilibrative nucleoside transporter expression in sickle cell disease and sickle cell trait. | British journal of haematology | 2023 | Yes |
| Association of Kidney Comorbidities and Acute Kidney Failure With Unfavorable Outcomes After COVID-19 in Individuals With the Sickle Cell Trait. | JAMA internal medicine | 2022 | Yes |
| A Health Literate Approach to Address Health Disparities: a Virtual Program for Parents of Children with Sickle Cell Trait. | Journal of communication in healthcare | 2022 | Yes |
| Age-Related Changes in Malaria Clinical Phenotypes During Infancy Are Modified by Sickle Cell Trait. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2021 | Yes |
| Balancing exercise risk and benefits: lessons learned from sickle cell trait and sickle cell anemia. | Hematology. American Society of Hematology. Education Program | 2018 | Yes |
Showing 5 of 55 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.